HPV vaccine, imiquimod, and metformin for advanced cervical or vulvar cancer
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical, vaginal, or vulvar cancer that is locally advanced or has spread, and surgery is not the first option
- You are newly diagnosed and have not yet received other investigational treatments
- You are generally able to take care of yourself (ECOG performance status 0–2)
- You are 18 years or older
- Your blood counts, kidney, and liver function are within acceptable ranges, checked within a month before starting
- You are not pregnant and agree not to breastfeed during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (QL1706) and a vaccine for people with cervical cancer that has not improved, came back, or spread. It aims to see if this combination can help control the cancer better than current options.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
Hear when a new Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.